Clinical data and phenotype characterization of plasma cells and erythroblasts from patients with MM or MGUS
| Patients, no. . | Stage . | Hb levels, g/dL . | Bone marrow aspirates . | Enriched erythroblast populations . | |||||
|---|---|---|---|---|---|---|---|---|---|
| CD38+ . | GpA+ . | CD38+ . | GpA+dim . | GpA+interm . | GpA+bright . | ||||
| Fas-L+ . | TRAIL+ . | ||||||||
| Myeloma patients | |||||||||
| Group A | |||||||||
| 01 | IIIB | 4.8 | 37.0 | 1.9 | 71.5 | 83.0 | 71.6 | 3.8 | 18.1 |
| 02 | IIIA | 6.5 | 29.2 | 4.5 | 44.1 | 55.6 | 56.7 | 12.4 | 20.3 |
| 03 | IIIA | 6.9 | 21.3 | 3.9 | 34.6 | ND | 35.5 | 41.1 | 13.8 |
| 04 | IIIB | 8.6 | 25.7 | 9.1 | 52.3 | 51.8 | 65.4 | 11.2 | 13.1 |
| 05 | II | 9.0 | 18.2 | 11.0 | 41.2 | 29.1 | 71.3 | 10.5 | 9.6 |
| 06 | IIIA | 7.8 | 45.1 | 2.6 | 73.0 | 90.0 | 68.4 | 9.3 | 11.0 |
| 07 | IIIA | 8.0 | 21.8 | 7.4 | 62.2 | 74.5 | 65.0 | 13.1 | 11.7 |
| 08 | IIIA | 7.6 | 48.0 | 2.3 | 29.0 | ND | 49.9 | 25.7 | 13.6 |
| 09 | IIIB | 6.5 | 39.7 | 5.5 | 37.0 | 52.2 | 47.1 | 16.0 | 26.3 |
| 10 | II | 8.6 | 61.4 | 6.1 | 47.5 | 31.0 | ND | ND | ND |
| 11 | II | 8.8 | 54.1 | 3.6 | 52.3 | 42.3 | 45.1 | 6.2 | 17.8 |
| 12 | IIIB | 8.1 | 35.3 | 2.4 | 50.7 | 66.0 | 59.5 | 21.3 | 9.1 |
| 13 | IIIA | 7.8 | 46.6 | 4.0 | 32.4 | 55.8 | 63.1 | 9.8 | 13.1 |
| 14 | IIIB | 6.7 | 41.8 | 3.1 | 88.6 | 98.0 | 70.1 | 2.9 | 19.4 |
| 15 | II | 8.8 | 30.5 | 5.2 | 43.5 | 61.5 | 44.5 | 23.0 | 21.1 |
| Mean ± SD | 37.0 ± 12.7 | 4.8 ± 2.6 | 50.6 ± 16.8 | 60.8 ± 21.1 | 58.0 ± 11.7 | 14.7 ± 10.2 | 15.5 ± 5.0 | ||
| Group B | |||||||||
| 01 | II | 12.1 | 14.2 | 10.5 | 23.1 | 6.5 | 23.4 | 17.1 | 47.9 |
| 02 | IIIA | 11.7 | 19.1 | 5.7 | 19.4 | 15.2 | 10.5 | 5.0 | 76.3 |
| 03 | I | 13.8 | 8.1 | 18.5 | 19.7 | ND | 17.2 | 28.1 | 43.7 |
| 04 | II | 12.6 | 9.4 | 13.0 | 11.4 | 21.5 | 18.1 | 9.1 | 62.0 |
| 05 | I | 13.5 | 24.7 | 4.3 | 17.3 | 18.5 | 33.5 | 21.8 | 39.2 |
| 06 | I | 14.1 | 18.0 | 9.0 | 8.5 | 12.1 | ND | ND | ND |
| 07 | IIIA | 12.8 | 31.6 | 4.8 | 30.5 | 11.0 | 13.3 | 16.1 | 60.0 |
| 08 | II | 13.1 | 17.0 | 9.1 | 23.1 | 10.6 | 28.8 | 11.1 | 49.5 |
| 09 | I | 15.0 | 18.3 | 11.4 | 5.6 | 11.4 | 15.6 | 13.6 | 58.8 |
| 10 | IIIA | 11.9 | 15.1 | 15.0 | 24.6 | 30.4 | 38.3 | 21.1 | 35.1 |
| 11 | I | 13.6 | 17.1 | 20.8 | 6.3 | 9.8 | 19.1 | 12.0 | 60.2 |
| 12 | IIIA | 12.5 | 22.4 | 9.4 | 41.0 | 33.1 | 16.8 | 4.6 | 68.3 |
| 13 | II | 13.1 | 12.0 | 11.4 | 8.0 | 20.3 | 21.3 | 25.4 | 53.0 |
| Mean ± SD | 17.4 ± 6.3 | 10.9 ± 4.9 | 18.3 ± 10.4 | 16.7 ± 8.3 | 21.3 ± 8.3 | 15.4 ± 7.6 | 54.5 ± 12.0 | ||
| MGUS patients | |||||||||
| 01 | 13.4 | 4.2 | 9.5 | 11.4 | 7.1 | 15.5 | 23.0 | 59.1 | |
| 02 | 11.9 | 10.2 | 4.7 | 18.4 | 3.4 | 9.3 | 18.8 | 67.0 | |
| 03 | 14.3 | 3.6 | 12.0 | 9.4 | 6.2 | 30.0 | 27.2 | 39.6 | |
| 04 | 15.1 | 5.5 | 18.1 | 6.5 | 11.0 | 11.6 | 7.7 | 74.0 | |
| 05 | 12.3 | 4.6 | 19.4 | 7.5 | 4.1 | 28.8 | 32.0 | 36.3 | |
| 06 | 13.1 | 6.8 | 11.3 | 14.1 | 8.6 | 13.9 | 12.5 | 70.2 | |
| 07 | 14.0 | 3.9 | 10.1 | 4.3 | ND | ND | ND | ND | |
| Mean ± SD | 5.5 ± 2.3 | 12.1 ± 5.0 | 10.2 ± 4.8 | 6.7 ± 2.8 | 18.1 ± 8.9 | 20.2 ± 9.0 | 57.7 ± 16.1 | ||
| Patients, no. . | Stage . | Hb levels, g/dL . | Bone marrow aspirates . | Enriched erythroblast populations . | |||||
|---|---|---|---|---|---|---|---|---|---|
| CD38+ . | GpA+ . | CD38+ . | GpA+dim . | GpA+interm . | GpA+bright . | ||||
| Fas-L+ . | TRAIL+ . | ||||||||
| Myeloma patients | |||||||||
| Group A | |||||||||
| 01 | IIIB | 4.8 | 37.0 | 1.9 | 71.5 | 83.0 | 71.6 | 3.8 | 18.1 |
| 02 | IIIA | 6.5 | 29.2 | 4.5 | 44.1 | 55.6 | 56.7 | 12.4 | 20.3 |
| 03 | IIIA | 6.9 | 21.3 | 3.9 | 34.6 | ND | 35.5 | 41.1 | 13.8 |
| 04 | IIIB | 8.6 | 25.7 | 9.1 | 52.3 | 51.8 | 65.4 | 11.2 | 13.1 |
| 05 | II | 9.0 | 18.2 | 11.0 | 41.2 | 29.1 | 71.3 | 10.5 | 9.6 |
| 06 | IIIA | 7.8 | 45.1 | 2.6 | 73.0 | 90.0 | 68.4 | 9.3 | 11.0 |
| 07 | IIIA | 8.0 | 21.8 | 7.4 | 62.2 | 74.5 | 65.0 | 13.1 | 11.7 |
| 08 | IIIA | 7.6 | 48.0 | 2.3 | 29.0 | ND | 49.9 | 25.7 | 13.6 |
| 09 | IIIB | 6.5 | 39.7 | 5.5 | 37.0 | 52.2 | 47.1 | 16.0 | 26.3 |
| 10 | II | 8.6 | 61.4 | 6.1 | 47.5 | 31.0 | ND | ND | ND |
| 11 | II | 8.8 | 54.1 | 3.6 | 52.3 | 42.3 | 45.1 | 6.2 | 17.8 |
| 12 | IIIB | 8.1 | 35.3 | 2.4 | 50.7 | 66.0 | 59.5 | 21.3 | 9.1 |
| 13 | IIIA | 7.8 | 46.6 | 4.0 | 32.4 | 55.8 | 63.1 | 9.8 | 13.1 |
| 14 | IIIB | 6.7 | 41.8 | 3.1 | 88.6 | 98.0 | 70.1 | 2.9 | 19.4 |
| 15 | II | 8.8 | 30.5 | 5.2 | 43.5 | 61.5 | 44.5 | 23.0 | 21.1 |
| Mean ± SD | 37.0 ± 12.7 | 4.8 ± 2.6 | 50.6 ± 16.8 | 60.8 ± 21.1 | 58.0 ± 11.7 | 14.7 ± 10.2 | 15.5 ± 5.0 | ||
| Group B | |||||||||
| 01 | II | 12.1 | 14.2 | 10.5 | 23.1 | 6.5 | 23.4 | 17.1 | 47.9 |
| 02 | IIIA | 11.7 | 19.1 | 5.7 | 19.4 | 15.2 | 10.5 | 5.0 | 76.3 |
| 03 | I | 13.8 | 8.1 | 18.5 | 19.7 | ND | 17.2 | 28.1 | 43.7 |
| 04 | II | 12.6 | 9.4 | 13.0 | 11.4 | 21.5 | 18.1 | 9.1 | 62.0 |
| 05 | I | 13.5 | 24.7 | 4.3 | 17.3 | 18.5 | 33.5 | 21.8 | 39.2 |
| 06 | I | 14.1 | 18.0 | 9.0 | 8.5 | 12.1 | ND | ND | ND |
| 07 | IIIA | 12.8 | 31.6 | 4.8 | 30.5 | 11.0 | 13.3 | 16.1 | 60.0 |
| 08 | II | 13.1 | 17.0 | 9.1 | 23.1 | 10.6 | 28.8 | 11.1 | 49.5 |
| 09 | I | 15.0 | 18.3 | 11.4 | 5.6 | 11.4 | 15.6 | 13.6 | 58.8 |
| 10 | IIIA | 11.9 | 15.1 | 15.0 | 24.6 | 30.4 | 38.3 | 21.1 | 35.1 |
| 11 | I | 13.6 | 17.1 | 20.8 | 6.3 | 9.8 | 19.1 | 12.0 | 60.2 |
| 12 | IIIA | 12.5 | 22.4 | 9.4 | 41.0 | 33.1 | 16.8 | 4.6 | 68.3 |
| 13 | II | 13.1 | 12.0 | 11.4 | 8.0 | 20.3 | 21.3 | 25.4 | 53.0 |
| Mean ± SD | 17.4 ± 6.3 | 10.9 ± 4.9 | 18.3 ± 10.4 | 16.7 ± 8.3 | 21.3 ± 8.3 | 15.4 ± 7.6 | 54.5 ± 12.0 | ||
| MGUS patients | |||||||||
| 01 | 13.4 | 4.2 | 9.5 | 11.4 | 7.1 | 15.5 | 23.0 | 59.1 | |
| 02 | 11.9 | 10.2 | 4.7 | 18.4 | 3.4 | 9.3 | 18.8 | 67.0 | |
| 03 | 14.3 | 3.6 | 12.0 | 9.4 | 6.2 | 30.0 | 27.2 | 39.6 | |
| 04 | 15.1 | 5.5 | 18.1 | 6.5 | 11.0 | 11.6 | 7.7 | 74.0 | |
| 05 | 12.3 | 4.6 | 19.4 | 7.5 | 4.1 | 28.8 | 32.0 | 36.3 | |
| 06 | 13.1 | 6.8 | 11.3 | 14.1 | 8.6 | 13.9 | 12.5 | 70.2 | |
| 07 | 14.0 | 3.9 | 10.1 | 4.3 | ND | ND | ND | ND | |
| Mean ± SD | 5.5 ± 2.3 | 12.1 ± 5.0 | 10.2 ± 4.8 | 6.7 ± 2.8 | 18.1 ± 8.9 | 20.2 ± 9.0 | 57.7 ± 16.1 | ||
The 28 patients with MM were selected in relation to their peripheral hemoglobin levels (group A, ≤ 9 g/dL; group B, ≥ 11.5 g/dL). Erythroblasts obtained by magnetic sorting were distributed in relation to the fluorescence intensity of GpA expression as dim, intermediate, and bright flow cytometric pattern, namely, immature, partially differentiated, and mature erythroblasts, respectively. Numbers are percent of positive cells.
Hb indicates hemoglobin; ND, not done.